We are live on ! Find out more
KTTAW icon

Pasithea Therapeutics Warrants
KTTAW

5 hedge funds and large institutions have $23.5K invested in Pasithea Therapeutics Warrants in 2024 Q4 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, 2 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 5 → 5 (0)

1% less capital invested

Capital invested by funds: $23.8K → $23.5K (-$330)

1.41% less ownership

Funds ownership: 64.68% → 63.27% (-1.4%)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 2

Holders
5
Holders Change
–
Holders Change %
0%
% of All Funds
0.07%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
2
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
WAM
Warberg Asset Management
Illinois
-$213
2
CS
Clear Street
New York
-$1
Name Holding Trade Value Shares
Change 		Change in
Stake
KC
1
Kepos Capital
New York
$12K – – –
WAM
2
Warberg Asset Management
Illinois
$8.81K -$213 -8,300 -3%
AC
3
Armistice Capital
New York
$1.73K – – –
MG
4
Marex Group
$925 – – –
CS
5
Clear Street
New York
$2 -$1 -29 -29%

KTTAW Hedge Fund Activity: Q4 2024 in Review

5 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Pasithea Therapeutics Warrants (KTTAW) for Q4 2024, worth a combined $23.5K — down 1.4% from $23.8K a quarter earlier.

Fund positioning in KTTAW was balanced in Q4 2024: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 2 trimmed.

The largest seller was Warberg Asset Management, cutting an estimated $213.

  • 5 institutional investors held Pasithea Therapeutics Warrants (KTTAW) as of Q4 2024, unchanged from Q3 2024.
  • Funds reported $23.5K of Pasithea Therapeutics Warrants stock for Q4 2024, down 1.4% quarter-over-quarter.
  • 0 funds opened new Pasithea Therapeutics Warrants positions in Q4 2024 and 0 closed out.
  • The largest Pasithea Therapeutics Warrants seller in Q4 2024 was Warberg Asset Management, an estimated $213 sold.

Based on aggregated 13F filings for Q4 2024.